ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1163

Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis

Ji-Hyun Lee1, Jeesoo Kim2, Sang-Hyon kim1, Jong‑Seo kim2 and Chang-Nam son1, 1Keimyung University, Dalseo-gu, Daegu, Republic of Korea, 2seoul national university, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Biomarkers, proteomics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis with urinary sample is a fascinate approach without patient’s pain due to its non-invasive nature. In this study, we performed proteomic analysis of AS urinary samples. Our aim is to discover novel diagnostic urinary biomarkers in the AS.

Methods: A total of 50 urine samples from 20 AS and each 10 controls [rheumatoid arthritis (RA), gout, healthy control (HC)] were collected. We collected AS and HC samples only from young males (< 50 years of age). Label-free quantitative proteomics were preformed and the resulting datasets were analyzed by MaxQuant (Ver.1.6.2.3) with Uniprot human database. Differentially expressed proteins were determined based on the fold change and p-value from LFQ(label-free quantitation) intensities log2(fold change >=1.5) and p-value< 0.05.

Results: From all urinary samples analyzed by liquid chromatography and tandem mass spectrometry (LC-MS/MS), we identified 1,975 proteins. Among them, we first found six proteins were differentially upregulated in AS patient group compared to the control group: cystatin-A(CSTA), collagen alpha-1 chain (COL14A1), alpha-amylase 1A(AMY1A), syndecan-1(SDC1), S100-A6(S100A6) and phosphoinositide-3-kinase-interacting protein 1(PIK3IP1) (Table 1). Interestingly, some of these proteins were previously observed as urinary biomarkers in other disease. For example, alpha-amylase 1A was highly expressed in the urine of prostate cancer, S100-A6 in the urine of upper gastrointestinal cancer, and PIK3IP1 in the urine of exertional rhabdomyolysis.

Conclusion: Diagnosing AS based on non-invasive manner still remains a challenge. We performed quantitative proteomic profiling of the respective urine samples from 4 diseases, i.e., AS, RA, gout and HC, and thereby identified six potential urinary biomarkers for AS. We will conduct molecular biological validation studies.

Supporting image 1

Table 1. List of proteins with increased levels in the Urine of ankylosing spondylitis patients vs other control groups.


Disclosures: J. Lee, None; J. Kim, None; S. kim, None; J. kim, None; C. son, None.

To cite this abstract in AMA style:

Lee J, Kim J, kim S, kim J, son C. Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/proteomic-investigation-to-identify-urinary-biomarker-for-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proteomic-investigation-to-identify-urinary-biomarker-for-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology